Stay updated with breaking news from Aparnar parikh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
<p>In a study led by investigators from <a href="https://www.massgeneralbrigham.org/" target=" blank">Mass General Brigham</a>, <a href="https://wyss.harvard.edu/" target=" blank">the Wyss Institute for Biologically Inspired Engineering at Harvard University</a> and <a href="https://www.dana-farber.org/" target=" blank">Dana-Farber Cancer Institute</a>, in collaboration with researchers from across the country and beyond the U.S., researchers developed a low-cost, ultrasensitive blood test to detect minute levels of a cancer biomarker that is highly specific to multiple common cancers. Each test can be performed with merely half a drop of blood (25 microliters). The tool showed promise for early cancer detection and disease monitoring, and could potentially be used in conjunction with other tools for detection, risk stratification and treatment. Results are published in <a href=&quo ....
Pan-Cancer Biomarker Detected by Ultrasensitive Blood Test miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
HIV drug stabilizes disease progression in metastatic colorectal cancer miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
A recurrence occurs when cancer comes back after treatment. This can happen weeks, months, or even years after the primary or original cancer was treated. It is impossible to know for sure if the cancer will recur and timely detection of recurrence, as well as identification of patients at high risk of recurrence after surgery, can be challenging. Postsurgical circulating tumor DNA (ctDNA) analysis is a promising tool for the identification of patients with minimal residual disease. Now researchers at Massachusetts General Hospital (MGH) report they have evaluated the first test that detects cancer DNA circulating in the blood of patients following treatment without knowing the particular mutations that were present in the patient’s tumor. ....